col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world

Springer Science and Business Media LLC: Nature Reviews Immunology
  original article Date Title Authors   All Authors
1 [GO] 2021―Dec―17 Author Correction: Immune dysregulation and immunopathology induced by SARS-CoV-2 and related coronaviruses - are we our own worst enemy? Lok-Yin Roy Wong, Stanley Perlman
2 [GO] 2021―Dec―15 The state of complement in COVID-19 Behdad Afzali, Marina Noris, Bart N. Lambrecht, Claudia Kemper
3 [GO] 2021―Dec―13 Author Correction: SARS-CoV-2 and HIV-1 - A Tale of Two Vaccines Barton F. Haynes
4 [GO] 2021―Dec―07 SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact Marc Lipsitch, Florian Krammer, Gili Regev-Yochay, Yaniv Lustig, Ran D. Balicer
5 [GO] 2021―Dec―06 The germinal centre B cell response to SARS-CoV-2 Brian J. Laidlaw, Ali H. Ellebedy
6 [GO] 2021―Dec―06 Cross-reactive memory T cells abort SARS-CoV-2 infection Alexandra Flemming
7 [GO] 2021―Dec―03 Dexamethasone restrains neutrophils in severe COVID-19 Alexandra Flemming
8 [GO] 2021―Dec―03 Defective viral genomes can protect against SARS-CoV-2 variants and other respiratory viruses Alexandra Flemming
9 [GO] 2021―Nov―26 Immune dysregulation and immunopathology induced by SARS-CoV-2 and related coronaviruses - are we our own worst enemy? Lok-Yin Roy Wong, Stanley Perlman
10 [GO] 2021―Nov―05 Comparing neurological complications after COVID-19 vaccination and SARS-CoV-2 infection Alexandra Flemming
11 [GO] 2021―Nov―05 Foetal sex affects maternal and placental immune responses to SARS-CoV-2 Alexandra Flemming
12 [GO] 2021―Nov―05 SARS-CoV-2 Delta variant excels at membrane fusion, but not immune evasion Alexandra Flemming
13 [GO] 2021―Oct―19 The immunology of asymptomatic SARS-CoV-2 infection: what are the key questions? Rosemary J. Boyton, Daniel M. Altmann
14 [GO] 2021―Oct―05 Cross-reactive tissue-resident CD8+ T cells may provide first line of defence against SARS-CoV-2 Alexandra Flemming
15 [GO] 2021―Sep―14 Negative impact of the COVID-19 pandemic on routine childhood immunization: experience from Pakistan Muhammad Suleman Rana, Aamer Ikram, Muhammad Salman, Muhammad Usman, Massab Umair
16 [GO] 2021―Sep―08 T cell-oriented strategies for controlling the COVID-19 pandemic Ji Yun Noh, Hye Won Jeong, Jerome H. Kim, Eui-Cheol Shin
17 [GO] 2021―Aug―10 Poor nasal immunity can lead to severe COVID-19 Alexandra Flemming
18 [GO] 2021―Aug―10 Detecting future coronavirus pandemics Alexandra Flemming
19 [GO] 2021―Aug―09 Inflammasome activation at the crux of severe COVID-19 Setu M. Vora, Judy Lieberman, Hao Wu
20 [GO] 2021―Aug―09 Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape John S. Tregoning, Katie E. Flight, Sophie L. Higham, Ziyin Wang, Benjamin F. Pierce
21 [GO] 2021―Aug―04 Publisher Correction: SARS-CoV-2 and HIV-1 - a tale of two vaccines Barton F. Haynes
22 [GO] 2021―Jul―16 SARS-CoV-2 and HIV-1 - a tale of two vaccines Barton F. Haynes
23 [GO] 2021―Jul―01 Immunological mechanisms of vaccine-induced protection against COVID-19 in humans Manish Sadarangani, Arnaud Marchant, Tobias R. Kollmann
24 [GO] 2021―Jun―24 Understanding COVID-19 in Africa Sofonias K. Tessema, John N. Nkengasong
25 [GO] 2021―May―14 Single-cell atlases dissect tissue destruction by SARS-CoV-2 Alexandra Flemming
26 [GO] 2021―May―10 Author Correction: Will SARS-CoV-2 variants of concern affect the promise of vaccines? Ravindra K. Gupta
27 [GO] 2021―Apr―29 Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection Deborah Cromer, Jennifer A. Juno, David Khoury, Arnold Reynaldi, Adam K. Wheatley, Stephen J. Kent, Miles P. Davenport
28 [GO] 2021―Apr―29 Will SARS-CoV-2 variants of concern affect the promise of vaccines? Ravindra K. Gupta
29 [GO] 2021―Apr―19 Neutralizing monoclonal antibodies for treatment of COVID-19 Peter C. Taylor, Andrew C. Adams, Matthew M. Hufford, Inmaculada de la Torre, Kevin Winthrop, Robert L. Gottlieb
30 [GO] 2021―Apr―14 Seeing SARS-CoV-2 variants through the eyes of T cells Aljawharah Alrubayyi, Dimitra Peppa
31 [GO] 2021―Apr―13 Is IL-6 a key cytokine target for therapy in COVID-19? Simon A. Jones, Christopher A. Hunter
32 [GO] 2021―Apr―06 Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19 Aldo Bonaventura, Alessandra Vecchié, Lorenzo Dagna, Kimberly Martinod, Dave L. Dixon, Benjamin W. Van Tassell, et al. (+5)
33 [GO] 2021―Apr―01 Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination Sarah Cobey, Daniel B. Larremore, Yonatan H. Grad, Marc Lipsitch
34 [GO] 2021―Mar―15 The first 12 months of COVID-19: a timeline of immunological insights Thiago Carvalho, Florian Krammer, Akiko Iwasaki
35 [GO] 2021―Mar―12 Author Correction: Are COVID-19 vaccines safe in pregnancy? Victoria Male
36 [GO] 2021―Mar―05 COVID-19 vaccines: modes of immune activation and future challenges John R. Teijaro, Donna L. Farber
37 [GO] 2021―Mar―03 Are COVID-19 vaccines safe in pregnancy? Victoria Male
38 [GO] 2021―Feb―23 SARS-CoV-2 infection and COVID-19 in asthmatics: a complex relationship Chrysanthi Skevaki, Antonina Karsonova, Alexander Karaulov, Daria Fomina, Min Xie, Sharon Chinthrajah, et al. (+2)
39 [GO] 2021―Feb―20 Author Correction: Do rogue antibodies make the difference between mild versus severe COVID-19? Alexandra Flemming
40 [GO] 2021―Feb―09 Targeting autoantibodies in COVID-19 Isabela Pedroza-Pacheco, Persephone Borrow
41 [GO] 2021―Feb―04 Do rogue antibodies make the difference between mild versus severe COVID-19? Alexandra Flemming
42 [GO] 2021―Feb―04 Intracranial inflammatory mediators involved in SARS-CoV-2 neurological manifestations? Alexandra Flemming
43 [GO] 2021―Feb―04 SARS-CoV-2 variant evades antibodies whilst maintaining fitness Alexandra Flemming
44 [GO] 2021―Jan―13 What have we learnt so far from COVID-19? Peter C. Doherty
45 [GO] 2021―Jan―11 Immune readouts from the Oxford COVID-19 vaccine Yvonne Bordon
46 [GO] 2021―Jan―11 Super(antigen) target for SARS-CoV-2 Matthew Brown, Nina Bhardwaj
47 [GO] 2021―Jan―05 Endemic SARS-CoV-2 will maintain post-pandemic immunity Marc Veldhoen, J. Pedro Simas
48 [GO] 2020―Dec―18 Viral targets for vaccines against COVID-19 Lianpan Dai, George F. Gao
49 [GO] 2020―Dec―01 Mapping host restriction of SARS-CoV-2 Ester Gea-Mallorquí
50 [GO] 2020―Dec―01 B cell persistence and evolution to SARS-CoV-2 Aljawharah Alrubayyi
51 [GO] 2020―Dec―01 Cross-viral protection against SARS-CoV-2? Sophie G. Reed
52 [GO] 2020―Nov―19 Leukocyte trafficking to the lungs and beyond: lessons from influenza for COVID-19 Ronen Alon, Mike Sportiello, Stav Kozlovski, Ashwin Kumar, Emma C. Reilly, Alexander Zarbock, et al. (+2)
53 [GO] 2020―Nov―02 Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models David S. Khoury, Adam K. Wheatley, Mitchell D. Ramuta, Arnold Reynaldi, Deborah Cromer, Kanta Subbarao, et al. (+3)
54 [GO] 2020―Oct―21 Immunological considerations for SARS-CoV-2 human challenge studies Alexander D. Douglas, Adrian V. S. Hill
55 [GO] 2020―Oct―13 At the heart of COVID-19 Felix Clemens Richter
56 [GO] 2020―Oct―13 IL-18-dependent MAIT cell activation in COVID-19 Ester Gea-Mallorquí
57 [GO] 2020―Oct―13 Intestinal attenuation of COVID-19 inflammation Aljawharah Alrubayyi
58 [GO] 2020―Oct―06 Do cross-reactive antibodies cause neuropathology in COVID-19? Jakob Kreye, S. Momsen Reincke, Harald Prüss
59 [GO] 2020―Oct―06 Cross-reactive memory T cells and herd immunity to SARS-CoV-2 Marc Lipsitch, Yonatan H. Grad, Alessandro Sette, Shane Crotty
60 [GO] 2020―Oct―02 Fatty monocytes in COVID-19 Matthew D. Park
61 [GO] 2020―Oct―02 SARS-CoV-2 antibody seroconversion in care home Joan Shang, Alvaro Moreira
62 [GO] 2020―Sep―28 Keeping track of the SARS-CoV-2 vaccine pipeline Edward P. K. Parker, Madhumita Shrotri, Beate Kampmann
63 [GO] 2020―Sep―10 COVID-19 herd immunity: where are we? Arnaud Fontanet, Simon Cauchemez
64 [GO] 2020―Sep―10 The global response to the COVID-19 pandemic: how have immunology societies contributed? Faith Osier, Jenny P. Y. Ting, John Fraser, Bart N. Lambrecht, Marta Romano, Ricardo T. Gazzinelli, et al. (+23)
65 [GO] 2020―Sep―07 Coordinated and sustained immune memory responses after mild COVID-19 Aljawharah Alrubayyi
66 [GO] 2020―Sep―07 SARS-CoV-2 ORF9c: a mysterious membrane-anchored protein that regulates immune evasion? Fangfang Lu
67 [GO] 2020―Sep―07 Does a host restriction factor facilitate entry of SARS-CoV-2? Ester Gea-Mallorquí
68 [GO] 2020―Sep―04 Immunological considerations for COVID-19 vaccine strategies Mangalakumari Jeyanathan, Sam Afkhami, Fiona Smaill, Matthew S. Miller, Brian D. Lichty, Zhou Xing
69 [GO] 2020―Sep―01 Inhaled nanobodies against COVID-19 Gustavo Martinez-Delgado
70 [GO] 2020―Sep―01 Immune correlates of SARS-CoV-2 protection Matthew Brown
71 [GO] 2020―Sep―01 Long-lasting SARS-CoV-2-specific T cell memories Cansu Cimen Bozkus
72 [GO] 2020―Aug―24 Not just antibodies: B cells and T cells mediate immunity to COVID-19 Rebecca J. Cox, Karl A. Brokstad
73 [GO] 2020―Aug―21 Altered immune cell differentiation in the lungs of patients with critical COVID-19 Erinke van Grinsven, Kathrin Jansen
74 [GO] 2020―Aug―21 CD8+ T cells remember same bits of SARS-CoV-2 Julie M. Mazet, Ester Gea-Mallorquí
75 [GO] 2020―Aug―21 Attacking the defence: SARS-CoV-2 can infect immune cells Mariana Borsa, Julie M. Mazet
76 [GO] 2020―Aug―17 A cocktail of antibodies for COVID-19 therapy Dean B. Matthews
77 [GO] 2020―Aug―17 Shared CD8+ T cell receptors for SARS-CoV-2 Rachel Levantovsky, Verena van der Heide
78 [GO] 2020―Aug―17 Spatial resolution of SARS-CoV-2 lung infection Luisanna Pia
79 [GO] 2020―Aug―17 Author Correction: Pre-existing immunity to SARS-CoV-2: the knowns and unknowns Alessandro Sette, Shane Crotty
80 [GO] 2020―Aug―12 The type I interferon response in COVID-19: implications for treatment Jeong Seok Lee, Eui-Cheol Shin
81 [GO] 2020―Aug―11 Getting to the (germinal) centre of SARS-CoV-2 Felix Clemens Richter, Mariana Borsa
82 [GO] 2020―Aug―11 Antibody response to SARS-CoV-2 - sustained after all? Ewoud B. Compeer, Lion F. K. Uhl
83 [GO] 2020―Aug―11 SARS-CoV-2 vaccine - think globally, act locally Ester Gea-Mallorquí, Ewoud B. Compeer
84 [GO] 2020―Aug―10 After 62 years of regulating immunity, dexamethasone meets COVID-19 Derek W. Cain, John A. Cidlowski
85 [GO] 2020―Aug―10 Author Correction: Tissue damage from neutrophil-induced oxidative stress in COVID-19 Mireille Laforge, Carole Elbim, Corinne Frère, Miryana Hémadi, Charbel Massaad, Philippe Nuss, et al. (+2)
86 [GO] 2020―Aug―04 Publisher Correction: NK cells in COVID-19: protectors or opponents? Aljawharah Alrubayyi
87 [GO] 2020―Jul―31 IgGs drive COVID-19 myeloid hyperinflammation Matthew D. Park
88 [GO] 2020―Jul―30 NK cells in COVID-19: protectors or opponents? Aljawharah Alrubayyi
89 [GO] 2020―Jul―29 Tissue damage from neutrophil-induced oxidative stress in COVID-19 Mireille Laforge, Carole Elbim, Corinne Frère, Miryana Hémadi, Charbel Massaad, Philippe Nuss, et al. (+2)
90 [GO] 2020―Jul―29 T cell responses in patients with COVID-19 Zeyu Chen, E. John Wherry
91 [GO] 2020―Jul―20 Virus dissociated from inflammation in fatal COVID-19 Meriem Belabed
92 [GO] 2020―Jul―20 Antibody responses to SARS-CoV-2 short-lived Nicolas Vabret
93 [GO] 2020―Jul―10 T cell renaissance in COVID-19 Lee Garner, Liliana Cifuentes
94 [GO] 2020―Jul―10 CRISPRing for host genes regulating SARS-CoV-2 Fangfang Lu, Michael Tellier
95 [GO] 2020―Jul―10 SARS-CoV-2 on the neural battleground Clara Eléonore Pavillet, Tharini Ashtalakshmi Selvakumar
96 [GO] 2020―Jul―07 COVID-19 and influenza: preparing for the storm Matthew D. Park
97 [GO] 2020―Jul―07 SARS-CoV-2-specific T cells without antibodies Cansu Cimen Bozkus
98 [GO] 2020―Jul―07 Pre-existing immunity to SARS-CoV-2: the knowns and unknowns Alessandro Sette, Shane Crotty
99 [GO] 2020―Jul―02 A call to arms: helping family, friends and communities navigate the COVID-19 infodemic Heidi J. Larson
100 [GO] 2020―Jun―26 SARS-CoV-2: too infectious to handle? Clarissa Coveney, Jennifer Alderson
101 [GO] 2020―Jun―23 GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches Frederick M. Lang, Kevin M.-C. Lee, John R. Teijaro, Burkhard Becher, John A. Hamilton
102 [GO] 2020―Jun―22 Sex differences in immune responses in COVID-19 Matthew D. Park
103 [GO] 2020―Jun―22 Roles for eosinophils and basophils in COVID-19? Alexandra Tabachnikova, Steven T. Chen
104 [GO] 2020―Jun―22 Preclinical data from SARS-CoV-2 mRNA vaccine Nicolas Vabret
105 [GO] 2020―Jun―18 Severe COVID-19 in the young and healthy: monogenic inborn errors of immunity? Shen-Ying Zhang, Qian Zhang, Jean-Laurent Casanova, Helen C. Su
106 [GO] 2020―Jun―17 Optimizing safety surveillance for COVID-19 vaccines Rebecca E. Chandler
107 [GO] 2020―Jun―16 Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children Anne H. Rowley
108 [GO] 2020―Jun―12 A versatile mouse model of COVID-19 Helene Borrmann, Rachel E. Rigby
109 [GO] 2020―Jun―12 Publisher Correction: Risk factors for death from COVID-19 Myvizhi Esai Selvan
110 [GO] 2020―Jun―12 Passive antibody therapy in COVID-19 Jonathan Abraham
111 [GO] 2020―Jun―12 Author Correction: Complement as a target in COVID-19? Antonio M. Risitano, Dimitrios C. Mastellos, Markus Huber-Lang, Despina Yancopoulou, Cecilia Garlanda, Fabio Ciceri, John D. Lambris
112 [GO] 2020―Jun―12 SARS-CoV-2 has a sweet tooth Athena Cavounidis, Elizabeth H. Mann
113 [GO] 2020―Jun―11 Considering how biological sex impacts immune responses and COVID-19 outcomes Eileen P. Scully, Jenna Haverfield, Rebecca L. Ursin, Cara Tannenbaum, Sabra L. Klein
114 [GO] 2020―Jun―08 Dissecting antibody-mediated protection against SARS-CoV-2 Tomer Zohar, Galit Alter
115 [GO] 2020―Jun―05 Many paths to COVID-19 lymphocyte dysfunction Samarth Hegde
116 [GO] 2020―Jun―05 SARS-CoV-2 cross-reactivity in healthy donors Verena van der Heide
117 [GO] 2020―Jun―05 Immune evasion via SARS-CoV-2 ORF8 protein? Matthew D. Park
118 [GO] 2020―Jun―04 COVID-19 vaccines: neutralizing antibodies and the alum advantage Peter J. Hotez, David B. Corry, Ulrich Strych, Maria Elena Bottazzi
119 [GO] 2020―Jun―04 Author Correction: COVID-19: the vasculature unleashed Laure-Anne Teuwen, Vincent Geldhof, Alessandra Pasut, Peter Carmeliet
120 [GO] 2020―Jun―02 Blood clots and TAM receptor signalling in COVID-19 pathogenesis Greg Lemke, Gregg J. Silverman
121 [GO] 2020―Jun―02 Author Correction: Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages Miriam Merad, Jerome C. Martin
122 [GO] 2020―May―27 Risk factors for death from COVID-19 Myvizhi Esai Selvan
123 [GO] 2020―May―27 Kawasaki disease linked to COVID-19 in children Alvaro Moreira
124 [GO] 2020―May―27 Innate T cells in COVID-19: friend or foe? Verena van der Heide
125 [GO] 2020―May―26 Dysregulation of type I interferon responses in COVID-19 Dhiraj Acharya, GuanQun Liu, Michaela U. Gack
126 [GO] 2020―May―21 COVID-19: the vasculature unleashed Laure-Anne Teuwen, Vincent Geldhof, Alessandra Pasut, Peter Carmeliet
127 [GO] 2020―May―14 Modulation of immune crosstalk in COVID-19 Bérengère Salomé, Zafar Mahmood
128 [GO] 2020―May―14 SARS-CoV-2 likes it cool Alessandra Soares-Schanoski
129 [GO] 2020―May―11 BCG-induced trained immunity: can it offer protection against COVID-19? Luke A. J. O’Neill, Mihai G. Netea
130 [GO] 2020―May―06 Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages Miriam Merad, Jerome C. Martin
131 [GO] 2020―May―01 Will helminth co-infection modulate COVID-19 severity in endemic regions? Richard S. Bradbury, David Piedrafita, Andrew Greenhill, Siddhartha Mahanty
132 [GO] 2020―May―01 COVID-19: a case for inhibiting IL-17? Omar Pacha, Mary Alice Sallman, Scott E. Evans
133 [GO] 2020―Apr―30 Impaired interferon signature in severe COVID-19 Conor Gruber
134 [GO] 2020―Apr―30 Inactivated vaccine for SARS-CoV-2 Emma Risson
135 [GO] 2020―Apr―30 SARS-CoV-2-reactive T cells in patients and healthy donors Luisanna Pia
136 [GO] 2020―Apr―28 Neutralizing antibody response in mild COVID-19 Verena van der Heide
137 [GO] 2020―Apr―28 COVID-19 vaccine design: the Janus face of immune enhancement Peter J. Hotez, David B. Corry, Maria Elena Bottazzi
138 [GO] 2020―Apr―28 Cancer therapy tool informs COVID-19 vaccines Miriam Saffern
139 [GO] 2020―Apr―28 Does asthma make COVID-19 worse? Samarth Hegde
140 [GO] 2020―Apr―28 The trinity of COVID-19: immunity, inflammation and intervention Matthew Zirui Tay, Chek Meng Poh, Laurent Rénia, Paul A. MacAry, Lisa F. P. Ng
141 [GO] 2020―Apr―23 Complement as a target in COVID-19? Antonio M. Risitano, Dimitrios C. Mastellos, Markus Huber-Lang, Despina Yancopoulou, Cecilia Garlanda, Fabio Ciceri, John D. Lambris
142 [GO] 2020―Apr―23 Advancing scientific knowledge in times of pandemics Nicolas Vabret, Robert Samstein, Nicolas Fernandez, Miriam Merad
143 [GO] 2020―Apr―21 The potential danger of suboptimal antibody responses in COVID-19 Akiko Iwasaki, Yexin Yang
144 [GO] 2020―Apr―17 Macrophages: a Trojan horse in COVID-19? Matthew D. Park
145 [GO] 2020―Apr―17 Will we see protection or reinfection in COVID-19? Miyo Ota
146 [GO] 2020―Apr―17 A map of SARS-CoV-2 and host cell interactions Louise Malle
147 [GO] 2020―Apr―15 COVID-19: risk for cytokine targeting in chronic inflammatory diseases? Georg Schett, Michael Sticherling, Markus F. Neurath
148 [GO] 2020―Apr―14 Coronaviruses hijack the complement system C. Matthias Wilk
149 [GO] 2020―Apr―14 Human antibodies can neutralize SARS-CoV-2 Jovani Catalan-Dibene
150 [GO] 2020―Apr―09 COVID-19: immunopathology and its implications for therapy Xuetao Cao
151 [GO] 2020―Apr―06 Dysregulation of lung myeloid cells in COVID-19 Bérengère Salomé, Assaf Magen
152 [GO] 2020―Apr―06 In the eye of the COVID-19 cytokine storm Natalie Vaninov
153 [GO] 2020―Apr―06 Fighting COVID-19 exhausts T cells Chang Moon


[de][en]

Last change 2021―Sep―04 16:13:39 UTC

© Daten-Quadrat 2021       Done in 0.010 sec